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Available online 29 November 2012Abstract Several potential clinical applications of stem cells rely on their capacity to migrate
into sites of inflammation where they contribute to tissue regeneration processes. Inflammatory signals are partially mediated
by chemokines acting via their receptors expressed on the target cells. Data concerning the repertoire and biological activities
of chemokine receptors in human adipose tissue derived stromal cells (ADSCs) are limited. Here we show that CCR1 is one of the
few chemokine receptors expressed in ADSCs at a high level. CCR1 expression varies in ADSCs derived from different donors. It
sharply decreases in the early phase of ADSCs in vitro propagation, but further demonstrates relative stability. Expression of
CCR1 positively correlates with expression of SOX2, OCT4 and NANOG, transcription factors responsible for maintenance of the
stemness properties of the cells. We demonstrate that signaling via CCL5/CCR1 axis triggers migration of ADSCs, activates ERK
and AKT kinases, stimulates NFκB transcriptional activity and culminates in increased proliferation of CCR1+ cells accompanied
with up-regulation of SOX2, OCT4 and NANOG expression. Our data suggest that chemokine signaling via CCR1 may be involved
in regulation of stemness of ADSCs.
© 2012 Elsevier B.V. All rights reserved.Introduction
Adherent, fibroblastic cell populations have been isolated
from many connective tissues, and some have been found to
contain a subset of local stem/progenitor cells. Some ofAbbreviations: ADSCs, adipose tissue derived stromal cells; BCs,
peripheral blood mononuclear cells; BMSCs, bone marrow derived
stromal cells; ESCs, embryonic stem cells; GPCR, G-protein coupled
receptor; p, passage.
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http://dx.doi.org/10.1016/j.scr.2012.11.004these cell populations are suggested to be nonimmunogenic,
and may have the ability to migrate to injured or inflamed
sites. Those features support their potential clinical appli-
cations including treatment of immune, cardiovascular and
degenerative diseases (osteoarthritis and osteoporosis), and
their use as drug delivery vehicles (Caplan, 2007; Gimble et
al., 2007).
It has been suggested that similarly to embryonic stem
cells (ESCs), stemness-related properties of some stromal
stem/progenitor cells are supported by regulatory networks
of transcription factors OCT4, SOX2 and NANOG (Greco et
al., 2007; Ng and Surani, 2011; Park et al., 2012; Riekstina et
al., 2009). When over-expressed, these factors reprogram
differentiated cells to an embryonic-like state designated as
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the morphology and growth characteristics of ESCs and
express ESC marker genes (Takahashi et al., 2007).
Stromal cells with stem/progenitor-like properties can be
found in a diverse range of tissues and organs (Parekkadan and
Milwid, 2010). White adipose tissue is considered as a rich
source of stromal cells due to its simple harvesting methods
and high numbers of isolated cells (Gimble et al., 2007).
Growth kinetics, immunogenic characteristics, in vitro differ-
entiation potential, senescence ratio and angiogenic activity
of adipose tissue derived stromal cells (ADSCs) (also known as
adipose-derived “mesenchymal stem cells”) are comparable
with stromal cells obtained from other sources; however,
several differences have been reported (De Ugarte et al.,
2003; Izadpanah et al., 2006; Noel et al., 2008; Wagner et al.,
2005; Winter et al., 2003).
Purification of homogenous functionally relevant stem/
progenitor cells from adipose tissue is still a challenge.
Widely used methods of ADSC isolation include separation of
adipose tissue stromal vascular fraction, followed by sorting
according to the immunophenotype guidelines suggested by
the International Society for Cellular Therapy, and selection
of a plastic adherent population (Dominici et al., 2006). It has
become clear that this method yields highly heterogeneous
populations with only a fraction of cells with stem/progenitor
characteristics (Gimble et al., 2010; Madonna et al., 2009;
Tallone et al., 2011). Heterogeneity of initial populations
may result in unpredictable effects and non-reproducible
results, and therefore it remains one of the key problems in
the field.
Numerous clinical applications of stromal cell populations
isolated from different tissues rely on the migration and
homing of therapeutic cells in the site of injury or inflamma-
tion (Chamberlain et al., 2007). Also, it has been suggested
that inflammatory conditions result in activation and direc-
tional movement of endogenous cells to the sites of injury
where they participate in the processes of tissue regeneration.
Signals of inflammation are partly mediated by chemokines.
These signaling molecules act via binding to their seven-
transmembrane receptors belonging to the G-protein coupled
receptor (GPCR) family. Chemokines and their receptors play
essential roles in the immune system by regulating mobiliza-
tion and migration of several cell types including neutrophils
and B- and T-lymphocytes (Bendall, 2005). Also, chemokines
are associated with a variety of other cellular functions
including proliferation, differentiation and establishment of
cellular polarity. Several data also indicate that chemokines
have cell type and concentration dependent anti- and pro-
apoptotic effects (Vlahakis et al., 2002). Twenty chemokine
receptors and approximately 50 chemokines are identified in
humans.
Bone marrow derived stromal cells (BMSCs) express several
chemokine receptors (CCR1, CCR4, CCR6, CCR7, CCR9, CCR10,
CXCR4, CXCR5, CXCR6, CX3CR1), and respective chemokines
induce migration of BMSCs in vitro (Fox et al., 2007;
Honczarenko et al., 2006; Ruster et al., 2006; Sordi et al.,
2005; Von Luttichau et al., 2005; Wynn et al., 2004). Data
concerning chemokine system in ADSCs are very limited. It
has been demonstrated that ADSCs are chemotactic in vitro,
but, compared to BMSCs, ADSCs express a smaller subset of
chemokine receptors (CCR1, CCR7, CXCR4, CXCR5 and
CXCR6) (Baek et al., 2011).Here we analyze the entire repertoire of chemokine
receptors in human ADSCs, peripheral blood mononuclear
cells and dermal fibroblasts, and show that CCR1 is one of the
few chemokine receptors highly expressed in ADSCs. Interest-
ingly, expression of CCR1 in different pools of ADSCs positively
correlates with the expression levels of the stem cell marker
genes SOX2, OCT4 and NANOG, whereas exposure of ADSCs to
CCL5, a ligand for CCR1, stimulates proliferation of CCR1+
cells accompanied with increased expression of SOX2, OCT4
and NANOG. Our results also show that CCR1 is an active
receptor in ADSCs, and signaling via the CCL5/CCR1 axis
triggers not only migration of cells but also activation of ERK
and AKT kinases as well as NFκB signaling pathway.Materials and methods
Cell culture
ADSCs were isolated from human subcutaneous adipose
tissue as described (Lin et al., 2007) with some modifications.
Minced adipose tissue was digested with 0.1% collagenase
(Gibco, Invitrogen, Carlsbad, CA, USA) in serum-free low
glucose Dulbecco's modified Eagle's medium (DMEM-LG)
(Gibco, Invitrogen) at 37 °C for 1.5 h, followed by neutraliza-
tion with normal growth medium (DMEM-LG) supplemented
with 10% fetal bovine serum (HI-FBS) (PAA, Pasching, Austria)
heat-inactivated at 56 °C for 30 min and 1% penicillin–
streptomycin (PEST) (Invitrogen). After centrifugation at
1000 rpm for 5 min, the cell pellet was incubated for 15 min
at room temperature (RT) in NH4Cl, passed through a 100-mm
nylon mesh (BD Biosciences Pharmingen, San Jose, CA, USA),
re-suspended in normal growth medium and plated at density
of 10,000 cells/cm2 (passage 0). Cells were propagated at
37 °C and 5% CO2 for 24 h, and non-adherent cells were
removed by changing the medium. Each splitting of the
confluent cells was considered as the next passage.
Immunophenotype of the isolated ADSCs was assessed as
CD73+/CD90+/CD105+/CD45−/CD34− (Supplementary Fig. 1).
Human peripheral bloodmononuclear cells were isolated using
a Histopaque-1077 (Sigma-Aldrich, Steinheim, Germany) den-
sity gradient centrifuge. Primary fibroblast cultures were
established by migration from skin explants placed onto
Primaria dish containing normal growth medium (Takashima,
2001). The donors of adipose tissue, skin fibroblasts and blood
mononuclear cells are described in the Supplementary Table 1.
For kinase activation assay, ADSCs were pre-incubated
overnight in serum-free DMEM-LG, treated with recombinant
CCL5 (PeproTech, Rock Hill, NJ, USA) for 10, 15 or 60 min,
washed with phosphate buffered saline (PBS) and lysed
directly in Laemmli sample buffer (60 mM Tris–Cl, pH 6.8, 2%
SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol
blue). Prolonged treatments of ADSCs were carried out in
Light medium (DMEM-LG containing 3% HI-FBS and 1% PEST)
supplemented with 50 ng/ml of CCL5 for 8, 24, 48 or 72 h.
Treatments were stopped by washing the cells with PBS,
trypsinization (trypsin–EDTA) (PAA), fractionation for total
RNA and protein isolations and immediate lysis in the respective
lysis buffer. Viability of ADSCs was tested using ViaLight™ plus
kit (Lonza, Basel, Switzerland) according to the manufacturer's
instructions.
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Total RNA was isolated using RNeasy micro kit (Qiagen,
Valencia, CA, USA) according to themanufacturer's instructions.
Complementary DNA was synthesized from 1 μg of total RNA
using SuperScript™ III Reverse Transcriptase (Invitrogen)
according to the manufacturer's protocol using oligo(dT)20.
We used 0.5 μl of cDNA per one PCR.
RT-PCR was performed using FIREPol® Master Mix (Solis
BioDyne, Tartu, Estonia) according to the manufacturer's
protocol. PCR products were separated on 1.5% agarose gel
and visualized by ethidium bromide staining. Quantitative
RT-PCR (qRT-PCR) was performed using Platinum® SYBR®
Green qRT-PCR SuperMix-UDG (Invitrogen). The levels of target
gene mRNAs and mRNA of glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) used for normalization were detected in
triplicates with LightCycler® 480 Real-Time PCR System (Roche
Applied Science, Basel, Switzerland). Data were analyzed using
Lightcycler 480 software (Roche) and calculations were carried
out using the comparative CT method. Primers used in the
current study are presented in Supplementary Table 2.
Statistical analysis was carried out using t-test (two sample
assuming unequal variances) (MS Excel). P values and co-
efficients of determination of a linear regression were
calculated using the GraphPad Prism software.
Cell transfection and luciferase assay
ADSCs were electroporated using human MSC Nucleofector®
kit and Nucleofector™ II Device (Lonza) with C-17 program
according to the manufacturer's protocol. We used 1500 ng of
a DNA construct encoding firefly luciferase reporter under
control of NFκB dependent promoter, and 500 ng of a plasmid
encoding Renilla luciferase under control of SV40 promoter.
After electroporation, the cells were propagated in normal
growth medium on a 48-well cell culture dish for 24 h
following treatment with CCL5 at different concentrations
(1, 10 or 50 ng/ml) in Light medium for 24 h. Transfected but
not treated cells were used as controls. Cells were washed
with PBS and lysed in 40 μl/well of passive lysis buffer
(Promega, Madison, WI, USA). Firefly and Renilla luciferase
activities were measured using Dual-Luciferase® Reporter
Assay System (Promega) and Ascent FL Fluoroscan (Thermo
Electron Corporation, Waltham, MA, USA) according to the
manufacturers' instructions. The obtained firefly luciferase
activity data were normalized with Renilla luciferase activity
values. The normalized firefly luciferase activity in the control
sample was set as 1 and the other samples were calculated
accordingly.
Western blot (WB)
Cells were re-suspended in RIPA buffer (50 mM Tris–HCl
[pH 7.4], 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% sodium
dodecyl sulfate) containing ProteoBlock™ protease inhibitor
cocktail (Fermentas Inc., Burlington, Ontario, Canada) and
incubated on ice for 30 min. Total protein concentrations
were measured using Pierce BCA Protein Assay kit; 20 μg of
total protein was separated on 10% polyacrylamide gel and
transferred to PVDF membrane (Millipore, Billerica, MA,
USA). The membrane was incubated in 5% non-fat dry milk(AppliChem, Darmstadt, Germany) in Tris buffered saline
(TBS)+0.05% Tween20 (Sigma) at RT for 1 h. Antibodies were
diluted in TBS-T containing 2.5% non-fat dry milk. The
antibodies used in the current study were: CCR1 (CKR-1
(H-52), sc-7934, 1:1500) (Santa Cruz Biotechnology, CA, USA),
AKT (9272, 1:1000) (Cell Signaling Technology, Beverly, MA,
USA), phospho-AKT (Ser473) (9271, 1:1000) (Cell Signaling
Technology), ERK (sc-154-G, 1:1500) (Santa Cruz Biotechnol-
ogy), phospho-ERK (sc-7383, 1:1500) (Santa Cruz Biotechnol-
ogy), SOX2 (1:750) (CeMines, Evergreen, CO, USA), and GAPDH
(G8795, 1:8000) (Sigma). Secondary HRP-conjugated anti-
rabbit, -goat or -mouse IgG antibodies were purchased from
Abcam (Cambridge, UK) (ab6721; ab6741; ab6728, respec-
tively, dilution 1:15,000). The proteins were visualized using
SuperSignal West Pico (ERK, phospho-ERK and AKT) or Femto
(phospho-AKT, CCR1 and SOX2) chemiluminescense substrate
kits (both Pierce Biotechnology Inc., Rockford, IL, USA).
Flow cytometry
Approximately 105 cells were harvested by trypsinization,
washed with PBS and blocked in 2% bovine serum albumin
(BSA) (PAA Laboratories GmbH, Pasching, Austria) in PBS.
Primary antibodies against CD34 (H-140) (Santa Cruz Biotech-
nology), CD45 (CALTAG Laboratories), CD73 and CD105 (both
BD Biosciences, Erembodegem-Aalst, Belgium) were added
directly into blocking solution at the dilution 1:500. Antibodies
against CD90 (Chemicon) and CCR1 (CKR-1 (C-20), Santa Cruz
Biotechnology, sc-6125) were diluted 1:100 in the blocking
solution. The cells were incubated with primary antibodies for
1 h on ice, washed for 10 min with PBS containing 0.5% BSA
and incubated with secondary antibodies Alexa Fluor 488
(A11017 or A31628, Molecular Probes, Eugene, OR, USA)
diluted in PBS+4% BSA at 1:400 for 45 min on ice. ADSCs
stained only with secondary antibody were used as a
nonreactive control. Cells were analyzed on Accuri™ C6 or
FACS Calibur flow cytometers (both BD Biosciences). Data
acquisition and analysis were performed using BD Accuri C6 or
CellQuest software, respectively (BD Biosciences).
Immunofluorescence (IF)
ADSCs were plated on slides (BD Biosciences) at a density of
approximately 3000 cells/cm2 and treated with 50 ng/ml of
CCL5 for 3 or 48 h. For bromodeoxyuridine (BrdU) staining,
cells were treated with CCL5 and 10 μM BrdU for 18 h. Cells
were washed 3 times with TBS and fixed in 4% paraformalde-
hyde in TBS for 15 min at RT and 15 min at +4 °C. For CCR1
immunostaining, the cells were treated with 0.1% Tween20 in
blocking solution (TBS supplemented with 2% bovine serum
albumin (BSA)) for 10 min at RT. For BrdU and CCL5 labeling,
the cells were permeabilized with 0.3% Tween20 in blocking
solution for 30 min. BrdU stained cells were additionally
treated with 2 N HCl for 8 min at RT with subsequent washing
with TBS containing 0.5% BSA. All cells were incubated in
blocking solution at +4 °C overnight. Cells were exposed to
CCR1 antibody CKR-1 (C-20), mouse monoclonal CCL5 capture
antibody from CCL5/RANTES DuoSet ELISA Development
System (R&D System, Wiesbaden, Germany), or BrdU antibody
mAbG3G4 (Developmental Studies Hybridoma Bank, Universi-
ty of Iowa, IA, USA) at dilutions of 1:300, 1:500 and 1:200,
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10 min with TBS containing 0.5% BSA and incubated with Alexa
Fluor 488 or Alexa Fluor 568 secondary antibodies (Molecular
Probes, A11017 or A11079) (dilutions 1:1000) for 1 h at RT.
CCR1, CCL5 and secondary antibodies were diluted in blocking
solution. BrdU antibody was diluted in blocking solution
supplemented with 0.3% Triton X-100 (Sigma). Cells were
mounted with Prolong Gold antifade reagent containing
4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen). The cells
were visualized under the fluorescence microscope Olympus
BX61 with UPLan SApo 40× or 20× objectives.
Cell migration assay
Cell migration assay was performed using a 24-well colorimetric
QCM Chemotaxis Cell Migration Assay kit (Millipore) with 8 μm
pore size polycarbonate membrane inserts. ADSCs were
subjected to overnight serum-starvation in DMEM-LG with
subsequent trypsinization and seeding of approximately
80,000 cells per insert in DMEM-LG. DMEM-LG supplemented
with 10 ng/ml of CCL5 was added to the lower chamber.
Migration assay was performed at 37 °C and 5% CO2 for 4 h.
Base medium without any supplement was used as a
negative control. Migratory cells on the membranes were
stained and visualized using a Zeiss Axiovert microscope
with 20× objective.
Enzyme-linked immunosorbent assay (ELISA)
The levels of CCL5 secreted into the growth medium were
measured using CCL5/RANTES DuoSet ELISA Development
System (R&D System). The cells were cultured for 3 days in
the normal growth medium. The media were collected,
centrifuged at 13,000 rpm for 5 min and immediately
used for analysis. ELISA was performed using high binding
ELISA plates (Greiner BioOne) at RT according to the
manufacturer's instructions. Optical density was measured
using the photospectrometer Spectramax 340 PC at the
wavelength 450 nm.
Results
ADSCs express a set of chemokine receptors
Expression of chemokine receptor transcripts in ADSCs, human
skin primary fibroblasts (FBs) and human peripheral blood
mononuclear cells (BCs) was analyzed using RT-PCR with 2
independent pairs of primers. All 20 receptors were expressed
in BCs. Analysis of four different pools of ADSCs showed that 13
chemokine receptors (CCR1, CCR2, CCR3, CCR5, CCR10,
CCR11, CXCR1, CXCR4, CXCR5, CXCR6, CXCR7, CX3CR1 and
XCR1) were expressed in ADSCs, whereas their expression
levels varied significantly (Fig. 1). Taking our data from four
independent experiments together, we conclude that 6
chemokine receptors (CCR1, CCR10, CCR11, CXCR4, CXCR6
and CXCR7) were expressed in all ADSC isolates at levels
comparable with that in BCs, whereas expression of CCR2,
CCR3, CCR5, CXCR1, CXCR5, CX3CR1 and XCR1was very low in
most of the ADSCs analyzed. Obtained data are mainly in line
with recently published results showing the expression ofCCR1, CCR2, CCR7, CXCR4, CXCR5 and CXCR6 in ADSCs (Baek
et al., 2011). CCR10, CCR11, CXCR6, CXCR7 and XCR1 were
expressed also in FBs. CCR1 was one of the few receptors
highly expressed in ADSCs, but not in FBs. It has been shown
that human BMSCs possess functional CCR1 (Honczarenko et
al., 2006), and the expression of CCR1 in ADSCs has been also
confirmed (Baek et al., 2011). Therefore, out of 6 chemokine
receptors found to be expressed in ADSCs at high levels, CCR1
has been chosen for further investigations.The expression levels of CCR1 vary in ADSCs isolated
from different donors
It has been reported that the expression of several
chemokine receptors decreases significantly in BMSCs as a
result of in vitro expansion of cells (Honczarenko et al.,
2006). We analyzed the expression of CCR1 in individual
pools of ADSCs isolated from different donors in the course of
prolonged in vitro propagation. Results of CCR1 mRNA
expression analyses in ADSCs derived from 9 individuals
(samples I–IX) and cultured two (p2) to twelve (p12)
passages are shown in Fig. 2A. CCR1 expression levels were
normalized using GAPDH expression levels and set as 1 for
ADSC test sample I (I p9). Data from other samples were
calculated relative to sample I p9. CCR1 expression was
detected in all samples. However, the levels of CCR1
expression varied notably between ADSCs isolated from
different donors. In general, CCR1 expression was the
highest in freshly isolated cells at passage p2 and decreased
significantly (more than 5 times) in the next passage (p3).
Also, expression of other analyzed chemokine receptors
except CXCR6 and CXCR7 decreased significantly by passage
p4 (Supplementary Fig. 2A). Further propagation of ADSCs in
vitro did not result in significant changes of CCR1 expression
in analyzed ADSC samples except sample IX that showed
more than 50 and 10 times reduction in the expression of
CCR1 in p4 compared to p2 and p3, respectively.
Flow cytometry analyses were exploited to estimate the
fraction of CCR1+ cells in ADSC populations using CCR1
antibody (Fig. 2B). Cells from samples III (p10) and VII (p2)
were used for these analyses. We also assessed CCR1+ cell
population in isolated BCs. The obtained results showed that
ADSC sample VII contained approximately 25% and sample III
approximately 4% of CCR1+ cells (Fig. 2B). These results
correlate well with the results of qRT-PCR analyses (Fig. 2A).
Two populations of cells expressing different levels of CCR1
were detected in BC samples, whereas approximately 69% of
cells were CCR1 positive. Analyses of expression of hemato-
poietic cell marker CD45 using flow cytometry showed that
all BCs were CD45+, whereas ADSC samples VII p2 and III p10
contained 4.5% and 1.7% of CD45+ cells, respectively
(Supplementary Figs. 1 and 2B). These data indicate that
hematopoietic CD45+ cells may only partly contribute to a
subset of CCR1+ cells in ADSCs.
IF analysis was used to estimate levels of CCR1 protein in
individual cells and to confirm flow cytometry analysis
results. Analysis of three different lineages of ADSCs (I p7,
V p8 and VI p12) using CCR1 antibody revealed that levels of
CCR1 protein varied significantly among individual cells
(Fig. 2C). The obtained results demonstrate high heteroge-
neity of ADSCs with respect to CCR1 expression between
Figure 1 ADSCs express mRNA for several chemokine receptors. The expression of 20 chemokine receptors was analyzed in ADSCs,
fibroblasts (FBs) and peripheral blood mononuclear cells (BCs) by RT-PCR. GAPDH and chemokine receptor cDNAs were amplified for 22 and
40 cycles, respectively.
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level of individual cells.Expression of CCL5 and CCL3 in ADSCs
Chemokine receptor CCR1 is known to interact with several
chemokines including CCL3, CCL5, CCL7, CCL15 and CCL23,
whereas CCL3 and CCL5 have the highest binding affinity
(Neote et al., 1993). Results of analysis of expression of CCL5Figure 2 Levels of CCR1 expression are individually variable. (A)
(samples I–IX) cultured for different periods of time (p2–p12 indicati
expression levels were measured in triplicates, normalized with GAPD
other samples were calculated relative to sample I p9. (B) The portions
samples III and VII were analyzed using flow cytometry. (C) Immunostand CCL3mRNA in BCs, 6 independent pools of ADSCs and FBs
by RT-PCR are presented in Fig. 3A. High levels of expression
of both ligands were detected in BCs. Expression of CCL3 was
not detected in analyzed FBs, and a half of analyzed FB
cultures expressed very low levels of CCL5mRNA. In contrast,
all tested ADSC cultures expressed low levels of CCL5 mRNA.
Expression of CCL3 was observed in 3 out of 6 pools of ADSCs.
Since CCL5 mRNA expression was detected in all ADSC
samples, we analyzed it also by qRT-PCR in several ADSC
samples that were previously tested for CCR1 expressionLevels of CCR1 mRNA expression in ADSCs from nine individuals
ng the passage numbers) were analyzed by qRT-PCR. CCR1 mRNA
H mRNA expression level and set as 1 in sample I (I p9). Data from
of CCR1+ cells within peripheral bloodmononuclear cells and ADSC
aining of ADSCs using CCR1 antibody (red) and DAPI (blue).
Figure 3 ADSCs may be affected by endogenous CCL5 signaling. (A) Expression of CCR1 ligands CCL3 and CCL5 in peripheral blood
mononuclear cells (BCs), 6 samples of ADSCs (ADSCs 1–6) and skin primary fibroblasts (FBs 1–2) was examined by RT-PCR (CCL3/CCL5
and GAPDH targets were amplified for 40 and 20 cycles, respectively). (B) The level of CCL5 mRNA expression in different samples of
ADSCs (I, IV, V, VII, VIII) cultivated for different periods of time (passages p1–p12) was measured using qRT-PCR, normalized with
GAPDH expression level and set as 1 in the sample Ip9. The other samples were calculated accordingly. The data are presented as an
average mean of one measurement performed in triplicates±SD. Concurrently, concentrations of secreted CCL5 protein (pg/ml) in
the conditioning media of the samples I p2, I p9, VIII p2, VII p1, VII p3 and VII p4 were measured by ELISA; NA — not analyzed. (C) CCL5
protein in permeabilized naive or treated with 50 ng/ml of recombinant CCL5 ADSCs (left and right panels, respectively) was
examined using CCL5 antibody (red). Nuclear staining was performed using DAPI (blue) (40× magnification). (D) Proliferation and
viability of ADSCs cultured in the presence of 25 and 50 ng/ml of CCL5 for 24 and 48 h were tested using ViaLight™ plus kit. (E) Three
independent lineages of ADSCs were treated with 50 ng/ml of CCL5 for 8, 24, 48 and 72 h, and the level of CCL5mRNA expression was
measured in triplicates, normalized with GAPDH expression level and set as 1 in untreated samples. The data are presented as fold of
induction of CCL5 expression in CCL5 treated samples over untreated controls±SD; **pb0.01.
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p1, p2, p3, p4, p6 and p8). Cells were cultured for 3 days in
normal growth medium, and lysed for total RNA isolation.
CCL5 mRNA expression levels were normalized using GAPDH
expression levels and set as 1 in the sample I p9. Expression
of CCL5 in other samples was calculated based on the value
of sample I p9. Before lysis of cells, media of samples I p2
and I p9, VI p2, VII p1, VII p3 and VII p4 were collected and
analyzed for secreted CCL5 protein using ELISA. Data of both
analyses are presented in Fig. 3B. Expression of CCL5decreased dramatically during the propagation of ADSCs.
Secreted CCL5 was detected only in the media of the samples
with the highest expression of CCL5 mRNA (I p2 and VII p1).
Secretion of CCL5 was not detectable (less than 1 pg/ml) in
ADSCs analyzed at later passages and used in the functional
assays in the present study. Linear regression analysis revealed
no correlation between expression levels of CCR1 and CCL5
(coefficient of determination R2=0.0685).
IF analysis showed that a small number of ADSCs expressed
CCL5 protein and expression of CCL5 varied significantly
172 M.-L. Kauts et al.between cells (Fig. 3C and Supplementary Fig. 3). Cells
treatedwith recombinant CCL5 protein for 18 hwere used as a
positive control. Regardless of low levels of CCL5 protein, our
data suggest that CCR1 may be affected by endogenous CCL5
signaling in ADSCs. Nevertheless, co-localization of CCR1 and
CCL5 was detected only on some non-permeabilized ADSCs
treated with recombinant CCL5 for 30 min (Supplementary
Fig. 3C).
Proliferation and viability of ADSCs incubated in the
presence of 25 or 50 ng/ml CCL5 for 24 or 48 h were not
inhibited (Fig. 3D). In order to test whether CCL5 signaling
influences CCL5 expression in ADSCs, the cells were treated
with CCL5 for 8, 24, 48, and 72 h and the levels of CCL5
expression were measured by qRT-PCR in the control and
treated samples. The data are presented as an average mean
of three independent experiments±SD (Fig. 3E). Treatment
with CCL5 for 8, 24 or 72 h had no significant effect on
endogenous CCL5 expression. However, expression of CCL5
decreased approximately 2 times within 48 h in response to
exogenous CCL5.Figure 4 ADSCs respond to CCL5. (A) ADSCs were stimulated w
immunostaining using CCR1 antibody (red) and DAPI (blue). Non-stimul
different concentrations of CCL5 for 20 min. The levels of phospho-AK
WB. (C) CCR1, CCR3 and CCR5 expression levels in two ADSC samples w
mRNA expression levels and set as 1 in sample V (left panel). ADSCs w
were lysed and subjected to WB analysis using phospho-ERK, phospho
ADSCs towards 50 ng/ml of CCL5 (left panel) was examined using a mo
(right panel). The migratory cells were stained and observed under aADSCs respond to CCL5
CCR1 belongs to the GPCR family and is activated by several
ligands including CCL5. Upon ligand binding, GPCR may be
rapidly internalized (Drake et al., 2006). It has also been
reported that CCL5 as some other chemokines may exert its
biological effects in a GPCR independent manner via
interacting with specific cell surface glycosaminoglycan
chains and heparin sulfate proteoglycans (Martin et al.,
2001; Roscic-Mrkic et al., 2003; Slimani et al., 2003; Wu and
Yoder, 2009). To analyze effect of CCL5 on CCR1 subcellular
localization in ADSCs, the cells were treated with 50 ng/ml
of CCL5 for 3 h and subjected to immunostaining using CCR1
antibody. Localization of CCR1 protein was assessed in at
least 500 cells treated or untreated with CCL5 using
fluorescent microscopy, and representative images are
shown in Fig. 4A (right and left panels, respectively).
Approximately 10% of native ADSCs were positive for CCR1.
In response to CCL5 stimulation, the number of CCR1+ cells
decreased notably. The loss of CCR1 from the surface ofith 50 ng/ml of CCL5 for 3 h (right panel) and subjected to
ated cells are shown in the left panel. (B) ADSCs were treated with
T, phospho-ERK, AKT, ERK and GAPDH proteins were detected by
ere measured in triplicates by qRT-PCR, normalized with GAPDH
ere stimulated with 50 ng/ml of CCL5 for 10 min or 1 h, the cells
-AKT, ERK, AKT and GAPDH antibodies. (D) Migration capacity of
dified Boyden chamber. As a control, CCL5-free media were used
light microscope using 20× objective.
Figure 5 CCL5 induces NFκB transcriptional activity. (A) ADSCs
173CCL5/CCR1 axis regulates multipotency of human adipose tissue derived stromal cellsADSCs upon CCL5 stimulation might be a result of its
internalization suggesting functional interaction between
CCL5 and CCR1.
Several chemokines are known to mediate their effects
through mitogen activated protein kinases (MAPK or ERK1/2)
that are activated upon phosphorylation of their specific
tyrosine and threonine residues (Garrington and Johnson,
1999; Pearson et al., 2001). Also, stimulation of cells with
chemokines leads to the activation of PI3K that induces its
downstream effectors including AKT kinase activated via
phosphorylation of its serine residue 473 (Alessio et al.,
2010). It has been shown that stimulation of BMSCs with
several chemokines triggers activation of ERK and AKT kinases
(Honczarenko et al., 2006). To assess, whether CCL5 leads to
the activation of the same signaling cascades in ADSCs, the
cells were treated with CCL5 at different concentrations
(1, 10, 25 and 50 ng/ml corresponding to 0.13, 1.3, 3.2 and
6.4 nM) for 20 min following WB analysis using antibodies
specific for total and phosphorylated forms of ERK and AKT
kinases (Fig. 4B). ERK and AKT kinases were activated in a
CCL5 concentration dependent manner. Activation of the
kinases was achieved at the CCL5 concentration of 1 ng/ml;
however, higher concentrations of CCL5 resulted in stronger
effects.
To identify the correlation between the kinase activation
and CCR1 expression levels, two lineages of ADSCs express-
ing different levels of CCR1 were used (Fig. 4C, left panel).
These cells also expressed different levels of other CCL5
receptors, such as CCR3 and CCR5. The cells were treated
with 50 ng/ml of CCL5 for 10 min and 1 h and analyzed with
WB (Fig. 4C, right panel). Phosphorylation of ERK and AKT
kinases occurred already within 10 min upon CCL5 stimula-
tion. The intensity of ERK and AKT phosphorylation corre-
lated with CCR1 expression levels. ERK remained activated
and AKT phosphorylation decreased to the control level
following 1 h of treatment.
It has been shown that BMSCs are capable of migration
towards chemokines in vitro (Fox et al., 2007; Honczarenko
et al., 2006). Recent study suggests that ADSCs also migrate
in response to chemotactic stimuli (Baek et al., 2011). In the
current study the Boyden chamber test was used to assess
the ability of ADSCs to migrate in the presence of CCL5.
Analysis showed that ADSCs were able to migrate towards
CCL5 (Fig. 4D).were co-transfected with plasmids encoding firefly luciferase
reporter under the control of NFκB dependent promoter and
Renilla luciferase reporter under SV40 promoter. The cells were
stimulated with CCL5 at indicated concentrations for 24 h.
Average firefly luciferase activity obtained from three indepen-
dent experimentsmeasured in three replicates were normalized to
Renilla luciferase values and presented as a fold of induction±SD
over luciferase activity in a non-stimulated ADSC sample (set as 1).
(B) ADSCs were stimulated with 50 ng/ml of CCL5 for indicated
periods of time and several NFκB target gene mRNA expression
levels were analyzed by qRT-PCR. Target gene mRNA levels were
measured in triplicates and normalized with GAPDH mRNA
expression level. The level of the particular gene expression in
the untreated control cells at the same time point was set as 1
(indicated by line). Data are represented as an average mean of
fold of induction of the indicated gene expression over non-
stimulated control±SD obtained from three independent experi-
ments. ((A, B) *pb0.05, **pb0.01.)CCL5 signaling activates NFκB and alters the
expression of NFκB target genes
It has been reported that simulation of CCR1 by CCL15 drives
the activation of nuclear factor-kappa-B (NFκB) in human
osteosarcoma cells (Jang et al., 2007). Also, some inflam-
matory cytokines of CXC family are known to stimulate the
NFκB signaling pathway in cancer and immune cells (Ye,
2001). To analyze the effect of CCL5 signaling on activation
of NFκB pathway in ADSCs, cells were co-transfected with a
construct encoding firefly luciferase under the control of
NFκB dependent promoter together with a plasmid encoding
Renilla luciferase under SV40 promoter following stimulation
of the cells with 50 ng/ml of CCL5. The average values of
firefly luciferase activity normalized with Renilla luciferase
activity obtained from three independent experimentsmeasured in three replicates±SD are presented in Fig. 5A.
Upon CCL5 treatment, NFκB transcriptional activity increased
in a dose dependent manner.
Analyses of the expression levels of several NFκB target
genes upon stimulation of ADSCs with 50 ng/ml of CCL5 using
qRT-PCR showed that expression of analyzed target genes
was up-regulated. The average means of induction of gene
expression levels over non-stimulated controls±SD obtained
from the analysis of three independent lineages of ADSCs are
shown in Fig. 5B. Treatment of ADSCs with CCL5 for 8 h led
to an increased expression of interleukin-6 (IL-6), and
174 M.-L. Kauts et al.matrix-metalloproteinase (MMP) 1 and 9. Expression of
MMP2 was up-regulated within 24 h. Expression levels of
tissue inhibitor of metalloproteinases (TIMP) 1 and 2,
inhibitors of MMPs, did not change (data not shown). These
data suggest that total activity of MMPs involved in ECM
remodeling processes required for initiation of migration
may be up-regulated in response to CCL5. Also, increased
expression of anti-apoptotic and pro-mitotic gene SURVIVIN
was detected. In contrast, expression of pro-apoptotic genes
BID and BAXα decreased. After 24 h of induction, the
expression levels of all tested genes except MMP1 and 2
decreased approximately to the control level.Expression of OCT4, SOX2 and NANOG positively
correlates with the expression of CCR1
Transcription factors regulating maintenance of the pluripo-
tent state in embryonic stem cells, such as SOX2, OCT4 and
NANOG, have been suggested to play similar roles also in adult
stem cells. Expression ofOCT4,NANOG and SOX2was analyzed
in ADSCs derived from 8 different individuals (I–VII and IX)
and cultured for different number of passages (p2–p12) by
qRT-PCR (Fig. 6A). Comparison of the expression of OCT4,
NANOG and SOX2 with the expression of CCR1 showed
statistically significant correlation between the gene
175CCL5/CCR1 axis regulates multipotency of human adipose tissue derived stromal cellsexpression levels. Linear regression analysis of gene expres-
sion levels revealed the following determination coefficients
and p values: R2(CCR1;OCT4)=0.78, p=0.0003; R2(CCR1;
NANOG)=0.62, p=0.004; R2(CCR1;SOX2)=0.67, p=0.0021;
R2(NANOG;OCT4)=0.65, p=0.0027; R2(SOX2;OCT4)=0.60,
p=0.0047; R2(SOX2;NANOG)=0.98, pb0.0001 (Supplementary
Fig. 4).
To explore whether CCL5 signaling induces alterations in
the expression levels of CCR1 and multipotency genes OCT4,
SOX2, NANOG, ADSCs were treated with 50 ng/ml of CCL5 for
indicated periods of time. CCR1, OCT4, SOX2 and NANOG
mRNA expression levels in induced and non-induced cells were
measured by qRT-PCR. The average induction of the gene
expression levels over non-treated controls±SD obtained from
three independent experiments are shown in Fig. 6B. Expres-
sion of receptor CCR1 and multipotency genes OCT4, NANOG
and SOX2 increased after 48 h of treatment and remained
slightly elevated for 72 h following induction with CCL5. To
confirm the qRT-PCR results, ADSCs were treated with CCL5
for 48 h, and cell lysates were subjected to WB analysis using
CCR1 and SOX2 antibodies (Fig. 6C). Compared with non-
stimulated cells, the levels of CCR1 and SOX2 proteins were
increased within 48 h in response to CCL5.
CCL5 signaling up-regulated SURVIVIN expression within
8 h. Increase of CCR1, OCT4, NANOG and SOX2 expression was
detected after 48 h of treatment initiation. These data
suggest that CCL5 may stimulate proliferation of ADSCs and,
in particular, CCR1+ cells. To test this hypothesis, the cells
were treated with 50 ng/ml of CCL5 and 10 μM BrdU for 18 h,
and assessed for a portion of BrdU+ cells by IF. ADSCs exposed
only to BrdU were used as a control. Cells considered as DAPI+
and BrdU+/DAPI+ are depicted in the left panel of Fig. 6D.
BrdU incorporation was assessed in at least 200 DAPI+ ADSCs
isolated from three donors, and the data of cell counting are
presented as an average mean of BrdU+/DAPI+ cells±SD in the
right panel of Fig. 6D. Cell counting revealed that approxi-
mately 11.4±4.2% of ADSCs were positive for BrdU. Treatment
with CCL5 led to increase of BrdU+ ADSCs to 16.4±4%. Since
double staining of the cells for CCR1 and BrdU was inefficient
for technical reasons, the portion of CCR+ cells in ADSCs
treated with CCL5 for 48 h was assessed using flow cytometry.
The data of a representative experiment performed using
ADSCs VIII p7 are shown in Fig. 6E. Amount of CCR1+ cellsFigure 6 Expression of OCT4, NANOG and SOX2 correlates with the
and CCR1 were analyzed in 9 pools of ADSCs (I–IX) cultivated for
expression levels were measured in triplicates, normalized with GAP
expression levels in other samples were calculated relatively to the s
indicated periods of time. OCT4, NANOG, SOX2 and CCR1 mRNA ex
GAPDH expression level. The level of the particular gene expression i
(indicated by line). The data are represented as an average mean o
non-stimulated control±SD obtained from three independent experime
of CCL5 for 48 h, if indicated. The cell lysates were subjected to W
were treated with 10 μM BrdU and, if indicated, 50 ng/ml of CCL5 d
and Alexa Fluor 568 secondary antibodies and DAPI (blue). Pink nu
considered as DAPI+ (left panel). BrdU staining was assessed in a
calculated. Cell counting data are presented as an average mean of
was detected in 11.4±4.2% and 16.4±4% of DAPI+ cells in the cont
stimulated with 50 ng/ml of CCL5, if indicated, and the number o
antibody. Brown and orange lines indicate CCR1+ cells that are untre
with the secondary antibody were used as a negative control (black).was increased approximately 28±14% in response to CCL5
signaling.Discussion
Stromal cells derived from different tissues represent a
promising clinical tool for cell therapy targeting a variety of
diseases. Efficiency of the cell therapy depends highly on
the number of delivered cells and appropriate homing of the
cells in the recipient. Therefore, comprehensive under-
standing of the molecular mechanisms that regulate cell
migration and homing enhances safety and efficacy of cell
therapies.
The mechanisms of ADSC migration are still largely
unknown. Migration of ADSCs in vitro is shown to be induced
by several chemokines, VEGF, PDGF, LPA and TxA2 through
activation of their biologically active receptors (Amos et al.,
2008; Baek et al., 2011; Kang et al., 2005; Lee et al., 2008;
Yun et al., 2009). Besides, ex vivo expanded ADSCs are
capable of in vitro and in vivo migration towards tumor cells
that are known to secrete chemokines and cytokines (Lamfers
et al., 2009). However, the expression and biological activity
of chemokine receptors in ADSCs are poorly investigated.
Recently, Baek and co-authors have published a paper
describing expression of the six chemokine receptors
CCR1, CCR2, CCR7, CXCR4, CXCR5 and CXCR6 in ADSCs (Baek
et al., 2011). Here we show that ADSCs express transcripts
for 13 out of 20 chemokine receptors (CCR1, CCR2, CCR3, CCR5,
CCR10,CCR11,CXCR1,CXCR4,CXCR5,CXCR6,CXCR7, XCR1 and
CX3CR1). Most of the chemokine receptors are expressed at low
levels in ADSCs. CCR1 is one of the receptors showing relatively
high expression in ADSCs. Its expression also has high individual
variability with more than 50 fold differences in the mRNA
levels in ADSCs isolated from different donors. Moreover,
variations of CCR1 expression have been observed also at the
single cell level. These differences reflect the heterogeneity of
ADSCs, which is a common feature of these cells.
It has been shown that freshly isolated BMSCs contain
approximately 70% of CCR1+ cells, and their ratio decreases to
25–5% during culturing to passages 12–16, respectively
(Honczarenko et al., 2006). Our flow cytometry analyses of
different ADSC samples suggest that less than 25% of cells areexpression of CCR1. (A) Expression levels of OCT4, NANOG, SOX2
different periods of time (passages p2–p10) by qRT-PCR. The
DH mRNA expression level and set as 1 in sample I (I p9). Gene
ample I p9. (B) ADSCs were treated with 50 ng/ml of CCL5 during
pression levels were analyzed by qRT-PCR and normalized with
n the untreated control cells at the same time point was set as 1
f fold of induction of the particular gene mRNA expression over
nts; *pb0.05, ***pb0.001. (C) ADSCs were induced with 50 ng/ml
B analysis using CCR1, SOX2 and GAPDH antibodies. (D) ADSCs
uring 18 h and subjected to immunostaining using BrdU primary
clei were considered as BrdU+/DAPI+, and blue nuclei were
t least 200 DAPI+ cells, and a percentage of BrdU+ cells were
three independent experiments±SD (right panel). BrdU staining
rol and CCL5 stimulated samples, respectively. (E) ADSCs were
f CCR1+ cells was measured by flow cytometry using the CCR1
ated and treated with CCL5 ADSCs, respectively. ADSCs stained
176 M.-L. Kauts et al.positive for CCR1, and pools of BCs contained approximately
70% of CCR1+ cells. Our data show that CCR1 expression as well
as expression of several other chemokine receptors (CCR5,
CCR10, CXCR4 and CX3CR1) is highest in the freshly isolated
cells analyzed at passage p2. Expansion of ADSCs to the next
passage p3 causes dramatic reduction of expression of most
of the chemokine receptors except CXCR6 and CXCR7.
Down-regulation of chemokine receptors in isolated ADSCs
within first passages may partly be accounted for by the
possible presence of CCR1+ plastic adherent blood monocytes
(Weber et al., 2001; Yona and Jung, 2010). However, mono-
cytes are not dividing cells under regular in vitro culturing
conditions; if they contaminate a culture of dividing cells,
their portion decreases during in vitro culturing. Nevertheless,
our flow cytometry analyses have shown that the portion of
CCR1+ cells exceeds several times the portion of CD45+
hematopoietic cells in ADSCs even at p2, suggesting the
existence of non-hematopoietic CCR1+ cells in ADSCs. The
observed down-regulation of CCR1 expression is most likely a
result of the apoptosis of CCR1+ cells of non-hematopoietic
origin. Further culturing of ADSCs from passages p3 to p12
(approximately 6 weeks of in vitro cultivation) did not
significantly affect expression of CCR1 in majority of the
samples.
BMSCs and ADSCs also express detectable levels of the CCR1
ligand CCL5 mRNA (Honczarenko et al., 2006). Expression of
CCL5, similarly to expression of CCR1, is the highest in the
freshly isolated ADSCs, but it decreases within each subsequent
passage in all ADSCs analyzed. Interestingly, proliferation of
CCR1+ cells and the resulting increase of CCR1 expression in
response to exogenous CCL5 signaling are accompanied with a
decrease in CCL5 expression. This may be a result of a decrease
in a subset of CCL5+ cells in ADSC populations or transcriptional
down-regulation of CCL5 expression in CCR1+ cells. Although
expression of CCL5 has been detected in some single
permeabilized ADSCs by IF, levels of the secreted CCL5 protein
in the media of most ADSC cultures analyzed were lower than
1 pg/ml (detection threshold of the used ELISA kit). These data
can be explained by postulating that secreted CCL5 binds to its
receptors on CCR1, CCR3 or CCR5-positive ADSCs or CCL5
becomes sequestered by heparan sulfate proteoglycans or
glycosaminoglycan chains of some cell surface proteins, e.g.
CD44 (Roscic-Mrkic et al., 2003; Slimani et al., 2003). Taken
together, our data suggest that CCR1+ ADSCs may be a subject
of paracrine or autocrine regulation by CCL5.
It has been demonstrated that CCR1 is biologically functional
in BMSCs (Honczarenko et al., 2006). Here we have shown that
CCL5 induces biological responses via CCR1, indicating that the
CCL5/CCR1 axis is functional also in ADSCs. CCL5 may also bind
to the CCR3 and CCR5 receptors; however, according to our
data, expression of these receptors is very low or not detectable
in ADSCs. We show that CCL5 signaling leads to activation of the
NFκB pathway, which is known to be involved in the regulation
of cell proliferation, survival, migration and invasion processes
(Hayden and Ghosh, 2012; Wu and Zhou, 2010). NFκB
transcriptional activity as well as expression of several NFκB
target genes is altered in ADSCs in response to CCL5 treatment.
We demonstrate rapid up-regulation of genes encoding endo-
peptidases (MMP1, MMP2 and MMP9) that hydrolyze the
components of ECM (e.g. collagen, fibronectin, laminin), thus
contributing to migratory and wound healing processes (John
and Tuszynski, 2001). Up-regulation ofMMP points to the abilityof ADSCs to re-modulate ECM in response to CCL5 stimulation.
Furthermore, it is an indication of activation of migratory
mechanisms in ADSCs demonstrated by cell migration assay
here and by others (Baek et al., 2011). Nevertheless, further
analyses are needed to elucidate, whether CCR1+ ADSCs are
also capable of chemotaxis in vivo and whether these cells are
able to differentiate and contribute to processes of tissue
regeneration.
The NFκB pathway has been proposed to trigger pro- and
anti-apoptotic signals in different cells (Chu et al., 1997; Ryan
et al., 2007). Here we show that the NFκB pathway activated
upon CCL5 stimulation rather inhibits cell death in ADSCs.
CCL5 signaling suppresses the expression of pro-apoptotic
genes BID and BAXα, whereas expression of SURVIVIN, an
inhibitor of apoptosis and important positive regulator of cell
cycle activated in G2/M phases, increases (Chandele et al.,
2004). Moreover, we show that a number of BrdU+ and CCR1+
cells increases in response to CCL5 signaling after 18 and
48 h of treatment initiation, respectively. Taken together,
these data indicate that CCL5 induces proliferation of
CCR1+ ADSCs.
It has been suggested that molecular mechanisms regulat-
ing the undifferentiated state of stromal stem/progenitor
cells from different tissues are related to the expression of
distinct transcription factors, such as OCT4, SOX2 and NANOG
(Greco et al., 2007; Park et al., 2011; Saulnier et al., 2011).
Down-regulation of these factors is associated with loss of
multipotency and self-renewal, and is proposed to state the
beginning of subsequent differentiation steps (Meshorer and
Misteli, 2006; Ng and Surani, 2011; Pan et al., 2006). Here we
show that OCT4, SOX2 and NANOG are expressed in ADSCs;
however, expression of SOX2 has not been detected in some
pools of ADSCs, distinguished by the lower expression of other
multipotency genes and CCR1. Interestingly, the expression
levels of OCT4, NANOG and SOX2 demonstrated statistically
significant correlation with the expression levels of CCR1 in
ADSC samples. Linear regression analysis has revealed that the
coefficients of determination (R2) obtained for the levels of
CCR1 and multipotency gene expression are comparable with
that of multipotency genes, with SOX2/NANOG demonstrating
the highest R2=0.98. Moreover, the levels of multipotency
gene expression were elevated in concert with up-regulation
of CCR1 expression upon stimulation of ADSCs with CCL5.
There are at least two possible explanations of this phenom-
enon. First, the transcriptional up-regulation of multipotency
genes via factors unidentified in the present study may occur
at a single cell level. Second, since the increase in the gene
expression levels is detected following 48 h of treatment
initiation, it is more likely that higher mRNA and protein levels
occur due to the increased amount of CCR1+ cells demon-
strated here. These data suggest that one of the features of
“real” adipose tissue derived stem/progenitor cells ex-
pressing OCT4, NANOG and SOX2 may be the expression of
CCR1 receptor. The presented data suggest that the CCL5/
CCR1 axis participates in the regulation of ADSC stemness
and multipotency, and consequently may have an impact on
differentiation of ADSCs. Also, data presented here suggest
a possible method for separating populations of ADSCs
possessing higher stemness-related properties by exploiting
the expression of CCR1 receptor.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2012.11.004.
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